A call for more integrated cardiovascular safety assessment

Area of Science:

• Pharmaceutical Sciences
• Cardiovascular Research
• Drug Development

Background:

• Cardiovascular safety issues are a major reason for drug development failure.
• This failure has public health consequences and escalates drug development costs.
• Improved understanding of nonclinical and clinical cardiovascular risk predictors is needed.

Purpose of the Study:

• To address the need for better cardiovascular safety assessment in drug development.
• To foster collaboration among industrial, academic, and government scientists.
• To identify consensus points and recommendations for improving pharmaceutical cardiovascular safety evaluation.

Main Methods:

• Convened a three-day think tank in June 2009, sponsored by ILSI HESI.
• Brought together diverse experts in cardiovascular research and drug safety.
• Facilitated interactive discussions on challenges and opportunities in cardiovascular safety assessment.

Main Results:

• Identified key areas of consensus among experts.
• Formulated recommendations for enhancing the pharmaceutical cardiovascular safety paradigm.
• Highlighted opportunities for a more integrated and predictive drug development strategy.

Conclusions:

• Enhanced collaboration and integrated strategies can improve cardiovascular safety assessment.
• Addressing attrition due to cardiovascular concerns is crucial for public health and drug development efficiency.
• The workshop provided a foundation for future advancements in ensuring safe and effective medicines.